1 / 7

Bruno Lasserre, Président de l ’ Autorité de la concurrence

Trade in pharmaceutical products: is antitrust stepping in for economic reasons or overall public interest?. Bruno Lasserre, Président de l ’ Autorité de la concurrence. Annual Conference of LIDC, Prague, October 12, 2012.

allred
Download Presentation

Bruno Lasserre, Président de l ’ Autorité de la concurrence

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trade in pharmaceutical products: is antitrust stepping in for economic reasons or overall public interest? Bruno Lasserre, Président de l’Autorité de la concurrence Annual Conference of LIDC, Prague, October 12, 2012

  2. I. Parallel trade of pharmaceutical products: what are the strategies of the main players and their consequences?

  3. I. Parallel trade of pharmaceutical products: what are the strategies of the main players and their consequences? • How do wholesalers that engage into parallel trade differentiate their strategies in terms of prices, volumes, and distribution across EU countries ? • What impact on distribution in “exporting” and “importing” countries? • How does competition law strike the balance between imperatives of public health and defense of the legitimate economic interest of the pharmaceutical industry? Should “pure players” be treated the same way as other wholesalers ?

  4. II. Originators vs. Generics: what impact on distribution strategies?

  5. II. Originators vs. Generics: what impact on distribution strategies? • How does the penetration of generics alter distribution strategies ? • How do originator firms alter their product and distribution strategy when their patent expire ? • What limits may competition law set to such strategies?

  6. III. Distribution of non-prescription drugs: what is the state of play ?

  7. III. Distribution of non-prescription drugs: what is the state of play ? • What are the pros and cons of restrictions on the sale of non-prescription drugs outside pharmacies? If it were to be liberalized, what conditions should be observed? • What consequences on the wholesalers’ strategies ?

More Related